"
Impact of Drug-Drug Interaction between CDK4/6 Inhibitors and Proton Pump Inhibitors on Survival Outcomes in the Treatment of Metastatic Breast Cancer—Real World Data from a Portuguese Center"
written by Joana Reis, Inês Costa, Mariana Costa, Ana Valente, Catarina Almeida, Marta Freitas, Cláudia Caeiro, Catarina Fernandes, Nuno Tavares, Miguel Barbosa,
published by
Journal of Cancer Therapy,
Vol.13 No.5, 2022
has been cited by the following article(s):
|
[1]
|
Concomitant Use of Proton Pump Inhibitors and CDK4/6 Inhibitors in Metastatic Hormone-Positive Breast Cancer: A Real-World Cohort Study
Oncology,
2024
DOI:10.1159/000542693
|
|
|
|
|
[2]
|
Concomitant Proton Pump Inhibitor Use and Clinical Outcomes with Palbociclib or Abemaciclib in Metastatic Breast Cancer: A Multicenter Retrospective Study
Archive of International Journal of Cancer and Allied Science,
2024
DOI:10.51847/UMsvq09HXG
|
|
|
|
|
[3]
|
Mitigating the Risk of Drug Interactions in Cancer Patients Taking Oral Anticancer Agents: The Role of a Multidisciplinary Team-Based Medication Reconciliation
Cureus,
2023
DOI:10.7759/cureus.35324
|
|
|
|
|
[4]
|
Concomitant Use of Proton Pump Inhibitors and Palbociclib Among Patients With Breast Cancer
JAMA Network Open,
2023
DOI:10.1001/jamanetworkopen.2023.24852
|
|
|
|